Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Alerts
  • Advertising
  • Job board
  • Subscribe
  • Contact
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Author's Takes
  • Reviews
    • View all reviews ...
    • Aging (Jul 2022)
    • Next-Generation Sequencing in Medicine (Jun 2022)
    • New Therapeutic Targets in Cardiovascular Diseases (Mar 2022)
    • Immunometabolism (Jan 2022)
    • Circadian Rhythm (Oct 2021)
    • Gut-Brain Axis (Jul 2021)
    • Tumor Microenvironment (Mar 2021)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Commentaries
    • Concise Communication
    • Editorials
    • Viewpoint
    • Top read articles
  • Clinical Medicine
  • JCI This Month
    • Current issue
    • Past issues

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Author's Takes
  • In-Press Preview
  • Commentaries
  • Concise Communication
  • Editorials
  • Viewpoint
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Alerts
  • Advertising
  • Job board
  • Subscribe
  • Contact
The red blood cell death receptor and thrombosis
Nigel Mackman
Nigel Mackman
Published August 13, 2018
Citation Information: J Clin Invest. 2018;128(9):3747-3749. https://doi.org/10.1172/JCI122881.
View: Text | PDF
Commentary

The red blood cell death receptor and thrombosis

  • Text
  • PDF
Abstract

RBCs are the most abundant circulating cells in humans and typically comprise 35% to 45% of the blood volume (hematocrit). Anemia is associated with an increase in bleeding, and epidemiological studies have shown an association between an elevated hematocrit and thrombosis. RBCs may contribute to hemostasis and thrombosis via mechanisms that include platelet margination leading to an increase in the near-wall platelet concentration, blood viscosity, thrombin generation, and platelet activation. In this issue of the JCI, Klatt et al. report that binding of the Fas ligand FasL on the surface of platelets to its cognate receptor FasR on the surface of RBCs increases thrombin generation in vitro and thrombosis in mouse models. This represents a new mechanism by which RBCs contribute to thrombosis.

Authors

Nigel Mackman

×

Figure 1

Composition of hemostatic plugs and arterial and venous thrombi.

Options: View larger image (or click on image) Download as PowerPoint
Composition of hemostatic plugs and arterial and venous thrombi.
(A) Hem...
(A) Hemostatic plugs consist of a core of highly activated platelets surrounded by fibrin and a shell of less activated platelets. RBCs force the smaller platelets to the vessel wall where they can monitor vascular integrity. (B) Arterial thrombi are platelet rich with few RBCs. In the ferric chloride model of carotid artery thrombosis the first event is binding of RBCs to the endothelium and subsequent recruitment of platelets followed by formation of large platelet aggregates. Platelet-RBC interactions mediated by FasL-FasR may contribute to thrombosis in the mouse ferric chloride model. (C) Venous thrombi contain red regions composed of RBCs and fibrin and white regions composed of platelets. Platelet-RBC interactions via FasL-FasR may enhance thrombosis in the mouse inferior vena cava model.

Copyright © 2022 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts